LifeMD Earnings Call Highlights Aggressive Growth Push

Lifemd, Inc. ((LFMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

LifeMD’s latest earnings call struck an upbeat tone, underscoring strong subscriber momentum, robust double‑digit revenue growth, expanding margins in the latest quarter, and a debt‑free balance sheet. Management acknowledged near‑term EBITDA pressure from aggressive investment, but framed it as a deliberate trade‑off to capture GLP‑1 demand, scale new platforms, and drive meaningfully higher profitability by late 2026.

Subscriber Growth and User Engagement

LifeMD reported active subscribers up 16% year over year to roughly 322,000, adding more than 13,000 net new subscribers in Q4, its strongest quarterly gain in 2025. The platform is onboarding about 1,200 new patients per day and attracts over 120,000 unique daily visitors, highlighting strong consumer interest and an expanding funnel.

Revenue Growth Accelerates at Scale

Quarterly revenue reached $46.9 million in Q4, a 4% increase from the prior year period, showing continued growth even as the company scales. For full‑year 2025, revenue climbed to $194.1 million, up 25% versus 2024, confirming that the subscription base is translating into meaningful topline expansion.

Profitability Trends and Margin Expansion

Q4 gross margin expanded sharply to 87.1%, up 570 basis points year over year, lifting gross profit to $40.8 million, an 11% gain. Adjusted EBITDA rose to $4.8 million in Q4 and $15.3 million for 2025, up from $1.1 million and $3.7 million respectively, signaling improving operating leverage despite growth investments.

Balance Sheet Strength Supports Investment

The company ended Q4 with $36.8 million in cash and no debt, giving it considerable flexibility to fund strategic initiatives without near‑term financing pressure. This clean balance sheet underpins management’s willingness to lean into marketing and platform expansion despite short‑term earnings volatility.

GLP‑1 Weight Management Drives Momentum

Demand in weight management is surging, with new GLP‑1 program sign‑ups approaching roughly 700 per day so far in Q1 2026 and more than 80% of these patients going on branded therapies. Customer acquisition costs in the GLP‑1 business declined about 4% sequentially even as volumes doubled, suggesting improving efficiency in a high‑growth vertical.

Pharmacy and Fulfillment Boost Margins

LifeMD’s affiliate pharmacy is now licensed across all 50 states and processes around 20,000 prescriptions per month, solidifying control over the medication supply chain. In‑house fulfillment is nearing 70% of volume and, combined with its 503‑A compounding capability, is expected to add roughly 150–200 basis points to margins over time.

Strategic Partnerships and New Product Launches

The company launched oral Wegovy via a collaboration with Novo Nordisk and integrated the offering into its RexMD platform, expanding access to high‑profile obesity treatment. Management emphasized that LifeMD is among a select group of virtual providers working with pharmacies affiliated with major GLP‑1 manufacturers, with additional pharma partnership opportunities in the pipeline.

AI and Infrastructure Investments

LifeMD is investing heavily in artificial intelligence, including a dedicated team and plans to roll out AI‑driven clinical decision support in the first half of 2026. A beta virtual cardiology program across 30 states already uses AI‑supported intake, while broader automation is being embedded to improve G&A efficiency and make care delivery more scalable.

Expanded Benefits Coverage as a Growth Lever

The platform currently covers more than 110 million lives through payer contracts and expects to surpass 220 million by the end of Q2 2026 via an expanded partnership. Historically, insurance enablement has reduced customer acquisition costs by over 30%, so this coverage expansion could materially enhance both growth and marketing efficiency.

Aggressive Investment and Near‑Term EBITDA Drag

Management warned that Q1 2026 adjusted EBITDA will swing to a loss of $4–5 million, driven largely by discretionary sales and marketing spend. S&M is expected to jump to more than $30 million in Q1 from a typical $20–22 million range as LifeMD aggressively capitalizes on GLP‑1 demand and other high‑return opportunities.

GAAP Losses Narrow but Persist

Excluding a one‑time gain from a business sale, Q4 2025 GAAP net loss from continuing operations improved to $1.9 million compared with $6.8 million a year earlier. For the full year, GAAP net loss from continuing operations narrowed to $13.3 million from $26.3 million in 2024, showing progress but underscoring that LifeMD is still not GAAP profitable.

Women’s Health: Strong Demand, Slower Profitability

The new women’s health offering has seen very strong demand and roughly a 50% drop in customer acquisition costs over its first month, but conversion rates initially lagged expectations. Management projects about $10 million in first‑year revenue with a higher run rate by Q4, yet does not expect this segment to be EBITDA accretive until 2027.

Retention and Product Mix Risks

Early adherence signals are encouraging, with some on‑therapy retention metrics above 80%, but long‑term stickiness for newly launched oral therapies like Wegovy remains uncertain. Additionally, full‑year 2025 gross margin dipped about 50 basis points to 85.7% due to product mix, highlighting that growth in certain categories can pressure margins even as Q4 trends improved.

Operational and Disclosure Gaps

The company chose not to disclose specific subscriber counts for oral Wegovy or the full roadmap for compounded product expansion, leaving some visibility gaps for investors. Execution risk also remains as newer initiatives scale, with elements like insurance‑based lifetime value still to be fully validated.

Guidance and Outlook

LifeMD guided Q1 2026 revenue to $48–49 million with an adjusted EBITDA loss of $4–5 million, but expects to return to adjusted EBITDA profitability in Q2 as investments start to pay off. For full‑year 2026, the company projects $220–230 million in revenue and $12–17 million in adjusted EBITDA, targeting a Q4 2026 annualized run rate above $250 million in revenue and more than $25 million in adjusted EBITDA.

LifeMD’s call painted a picture of a digital health player leaning into growth, particularly around GLP‑1 weight management, pharmacy integration, and AI‑driven care, while steadily improving its profit profile. Investors will have to tolerate near‑term earnings volatility and some execution risk, but the combination of strong subscriber trends, accelerating platforms, and a debt‑free balance sheet suggests a company positioning itself for materially larger scale by 2026.